Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD). The data demonstrated that INTUNIV showed significant efficacy in reducing ADHD symptoms for patients taking the medication when compared to patients taking placebo at all measured time points up to 24 hours postdose.

The U.S. Food and Drug Administration (FDA) issued an approvable letter on June 20, 2007, regarding INTUNIV. Shire is conducting additional clinical work which is designed to enhance the label. Upon approval, INTUNIV will be the first selective alpha-2A receptor agonist indicated for the treatment of ADHD that may provide an important treatment option for patients and physicians.

Summary of Analyses

The pooled analysis evaluated results from these patients on a weight adjusted mg/kg basis from two similarly designed, randomized, double-blind, forced-dose titration, multicenter phase III trials. The primary efficacy measure for both studies was change in the ADHD Rating Scale (ADHD-RS-IV) total score from baseline to endpoint. All patient groups treated with INTUNIV showed significantly greater improvement in ADHD-RS-IV total score from baseline to endpoint than the placebo group (P<.001). The ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing their response to treatment.

The analysis also studied duration of effect using the Conners' Parent Rating Scale-Revised Short Form (CPRS-R), which is a comprehensive scale that used observer and self-report ratings to help assess ADHD and evaluate behavioral issues in children and adolescents. The CPRS-R asses
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. ... vegetable-glycol solution for use in portable vaporizers, which ... active ingredients in cannabis, cannabidiol offers consumers a ... devices, and other vaporizer technology. Photo ... naturally contains 483 different compounds which are currently ...
(Date:7/11/2014)... July 11, 2014 Patient engagement has ... consequently, organizations are turning to an assortment of ... As part of this evolving approach to patient ... communicate and engage patients throughout their experiences with ... empowerment. By mapping the patient journey and employing ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... SAN DIEGO, Aug. 26 CareFusion (NYSE: ... announced the national commercial launch of the AVA max® ... during kyphoplasty, a procedure for treating spinal compression fractures. ... represents a competitive breakthrough and is expected to enhance ...
... Inc. (Nasdaq: ALXA ) announced today that ... to Cypress Bioscience, Inc. (Nasdaq: CYPB).  The Staccato ... system designed to help people stop smoking.  The ... a well-validated smoking cessation approach by delivering nicotine via ...
Cached Medicine Technology:CareFusion Announces National Launch of Spinal Fracture Device 2CareFusion Announces National Launch of Spinal Fracture Device 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 2Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 4
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... York (PRWEB) July 11, 2014 ... , filed against Johnson & Johnson’s Ethicon Inc. ... Liebhard LLP notes that the Texas Attorney General’s ... company’s marketing of surgical mesh products used to ... According to a report from kens5.com, the probe ...
(Date:7/11/2014)... July 11, 2014 Butler Mobility has recently ... Inclined Platform Lifts . Previously the two standard colors ... new beautiful earth tone colors as standard colors at no ... in the home but will enhance the beauty of the ... any home color scheme or individual décor. , The new ...
(Date:7/11/2014)... (HealthDay News) -- Reducing the number of deer in ... disease and other tick-borne infections among people, new research ... be manipulated to reduce human interactions with deer, infected ... the researchers wrote. White-tailed deer are the primary ... to people. The study included nearly all the ...
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2
... Young adults whose mothers experienced psychological trauma during ... Irvine-led study found. The researchers discovered that this ... regions that control cell aging processes. The study results, ... of the National Academy of Sciences , point to ...
... 11th leading cause of death in the United States. Every ... Sadly, each year tens of thousands die by suicide. While ... warning signs exist. Often a simple question from a family ... and treatment. A new review in the August ...
... CHAPEL HILL, N.C. - Joanne M. Jordan, MD, MPH, director ... North Carolina at Chapel Hill, has received the 2011 Distinguished ... (RSS). The purpose of the award is to recognize ... enhancement of rural life and rural people. For more than ...
... cell phones have led to preventive policies in France, Israel, ... the health risks associated with exposure to the radiation energy ... of the Environmental Health Trust, in a timely and informative ... by Mary Ann Liebert, Inc. The interview is available free ...
... HealthDay Reporter , MONDAY, Aug. 1 (HealthDay News) -- ... acid DHA during pregnancy, their babies have fewer cold symptoms ... and 3 months of age, about 38 percent of babies ... symptoms, compared to about 45 percent of the babies whose ...
... , MONDAY, Aug. 1 (HealthDay News) -- Despite the ... -- which can be done at home or in day ... However, colon cleansing can cause serious side effects ranging ... the report say. Colon cleansing -- also called colonic ...
Cached Medicine News:Health News:UCI-led study links prenatal exposure to stress with accelerated cell aging 2Health News:Mayo Clinic: Primary physicians may hold key to suicide prevention 2Health News:Dr. Joanne Jordan receives Distinguished Service to Rural Life Award 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 3Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... have met the challenges of the ... exceptional performance and quality, they have ... worldwide. These grafts require no preclotting, ... infection, and ensure utmost thrombectomy safety. ...
... the challenges of the most demanding vascular ... exceptional performance and quality, they have earned ... grafts require no preclotting, resist dilatation and ... thrombectomy safety. Gore vascular grafts are also ...
... the newest vascular graft offering from W. ... vascular surgical products for more than two ... and compression problems that can lead ... all of the benefits of a ring ...
Medicine Products: